ITI-722 is primarily investigated for its potential therapeutic applications in neurological and psychiatric disorders. It acts as a selective modulator of specific neurotransmitter receptors, making it a candidate for treating conditions such as chronic pain, epilepsy, and anxiety. Due to its ability to cross the blood-brain barrier efficiently, it shows promise in targeting central nervous system pathways with high specificity. Research is ongoing to evaluate its efficacy in reducing neuronal hyperexcitability without significant sedative effects, which could offer advantages over existing treatments. Additionally, ITI-722 is being studied for its potential in substance use disorder interventions, particularly in modulating reward pathways associated with addiction. Its development is focused on achieving improved safety and tolerability profiles in long-term therapy.